Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Santiago Arroyo

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
RufinamideSantiago Arroyo
Epilepsy & Behavior : E&B|October 7, 2003
Translating monotherapy trials into clinical practice: a look into the abyssSantiago Arroyo, Emilio Perucca
Epileptic Disorders : International Epilepsy Journal with Videotape|August 14, 2003
Safety profile of levetiracetamSantiago Arroyo, Pamela Crawford
Data in Brief|June 10, 2025
Dataset for Multidimensional Poverty Index in Cali-ColombiaJhon James Mora Rodriguez, Diana Yaneth Herrera, José Santiago Arroyo
Frontiers in Neuroscience|February 16, 2024
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled studyJocelyn H Leu, An Vermeulen, Claudia Abbes, et al.
General Hospital Psychiatry|July 6, 2004
Psychiatric disorders, trauma, and MMPI profile in a Spanish sample of nonepileptic seizure patientsEva Baillés, Luis Pintor, Emili Fernandez-Egea, et al.
Epilepsia|June 4, 2009
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trialMartin J Brodie, William E Rosenfeld, Blanca Vazquez, et al.
Epilepsia|December 25, 2003
Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizuresSantiago Arroyo, Henning Anhut, Alan R Kugler, et al.
Epilepsia|April 16, 2002
Is refractory epilepsy preventable?Santiago Arroyo, Martin J Brodie, Giuliano Avanzini, et al.
Clinical Pharmacology and Therapeutics|November 8, 2018
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human StudyLeona E Ling, Jan L Hillson, Renger G Tiessen, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
RufinamideSantiago Arroyo
Epilepsy & Behavior : E&B|October 7, 2003
Translating monotherapy trials into clinical practice: a look into the abyssSantiago Arroyo, Emilio Perucca
Epileptic Disorders : International Epilepsy Journal with Videotape|August 14, 2003
Safety profile of levetiracetamSantiago Arroyo, Pamela Crawford
Data in Brief|June 10, 2025
Dataset for Multidimensional Poverty Index in Cali-ColombiaJhon James Mora Rodriguez, Diana Yaneth Herrera, José Santiago Arroyo
Frontiers in Neuroscience|February 16, 2024
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled studyJocelyn H Leu, An Vermeulen, Claudia Abbes, et al.
General Hospital Psychiatry|July 6, 2004
Psychiatric disorders, trauma, and MMPI profile in a Spanish sample of nonepileptic seizure patientsEva Baillés, Luis Pintor, Emili Fernandez-Egea, et al.
Epilepsia|June 4, 2009
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trialMartin J Brodie, William E Rosenfeld, Blanca Vazquez, et al.
Epilepsia|December 25, 2003
Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizuresSantiago Arroyo, Henning Anhut, Alan R Kugler, et al.
Epilepsia|April 16, 2002
Is refractory epilepsy preventable?Santiago Arroyo, Martin J Brodie, Giuliano Avanzini, et al.
Clinical Pharmacology and Therapeutics|November 8, 2018
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human StudyLeona E Ling, Jan L Hillson, Renger G Tiessen, et al.
Pageof 2